tariff talk lower ep guid overshadow strong
beat revenu order remain neutral
flu report signific beat revenue
gross order rais guidanc full year sale
sunni result cloud slightli reduc ep guidanc talk
relat tariff adjust outlook potenti tariff
impact margin detail avail guid
ep reduc coupl penni midpoint trade
slightli otherwis strong quarter stock price-to-earnings
multipl well comp group maintain neutral rate
hope better understand long-term potenti tariff impact
mix guidanc updat rais revenu growth
guidanc rang y/i y/i prior reflect substanti
beat quarter continu assum bp currenc
impact time co reduc oper margin
forecast prior guid non-
gaap ep prior guidanc incorpor potenti
gross margin headwind due tariff
tariff talk town management emphas
product convers import preserv
access life-sav cancer-fight technolog still
detail avail think uncertainti may pressur share
expect continu drive ep growth faster pace
sale growth also think worri potenti dip
busi china prematur stage worth watch
order growth particularli strong america emea
region expect order volum remain lumpi quarter
quarter hearten seem stem multipl
driver product revenu growth still outpac order growth
seem truebeam system continu instal quickli
valuat varian rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
varian report total revenu continu oper well
estim street result beat
oncolog proton revenu gross oncolog order compani
came forecast consensu
look varian post new probeam proton system
order quarter report proton revenu higher
model
gross oncolog order y/i constant currenc includ
y/i america y/i constant currenc emea y/i
declin constant currenc apac region
gross margin bp better model driven gross
margin oncolog revenu sg spend percentag revenu
bp estim spend slightli higher
forecast higher oper spend off-set gross margin beat result
oper margin line forecast thank larg revenu
beat non-gaap cent higher forecast
actualsbtig estimate varianceoncolog revenu revenu revenu gross order gross order incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
oncolog revenu forecast increas slightli strong
order growth quarter quarter continu outpac
estim proport trail order convert
oncolog product revenu leav forecast revenu convers rate
leav expect oncolog gross order unchang go
forward dollar basi expect continu lumpi quarter
quarter proton revenu reduc forecast off-set
higher-than-expect revenu quarter time revenu
recognit proton difficult predict
yet make substanti chang revenu outlook
choos await compani guidanc revenu estim year
increas result quarter order convert revenu servic
revenu grow instal base
forecast revenu growth midpoint
guidanc rang
 previous model gross margin street
despit signific beat gm estim quarter maintain
overal gm forecast reflect manag commentari
potenti impact tariff increas sg spend
percentag revenu meaning sinc underestim invest
quarter expect continu also increas spend
model non-gaap oper margin within revis
guidanc rang model non-gaap project tax rate
beyond chang model forecast non-gaap ep
within guidanc rang
beyond leav gross margin forecast unchang
alreadi includ sequenti step-down slightli
increas oper spend percentag revenu sg
continu model non-gaap tax rate ad slightli lower share
count revis result rel unchang outlook
gross incom ebit btig estim compani filingsnewold chang
varian rate neutral feel current valuat ntm
ep estim fair expens varian premium multipl
compani similar growth btig assign price target neutral-
rate stock risk includ halcyon adopt chang oper margin
capit spend slow hospit govern new
competit healthcar multipl gener trade lumpi quarterli
ntm johnsonjnjund bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discontinu non- dilut share net ex select calendar loss net product product product oper ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
